DRUG/MAKER              DESCRIPTION

CAMPTOSAR               Injectable ''second-line'' treatment after standard
Pharmacia & Upjohn      injectable 5-FU chemotherapy has failed; eventually
                        may be used with 5-FU as first-line treatment

ORZEL                   Oral 5-FU; studies show that it is as effective as
Bristol-Myers Squibb    intravenous versions

OXALIPLATIN             May become a primary treatment given intravenously;
Eli Lilly/Sanofi        shown by studies to work well with 5-FU

XELODA                  Oral 5-FU; also shown to be as effective as
Hoffman LaRoche         injectable 5-FU


DRUG/MAKER              REGULATORY STATUS

CAMPTOSAR               Has FDA approval
Pharmacia & Upjohn

ORZEL                   Seeking FDA approval for
Bristol-Myers Squibb    use in colon cancer

OXALIPLATIN             To be submitted for FDA
Eli Lilly/Sanofi        approval this year

XELODA                  Has FDA approval for
Hoffman LaRoche         breast cancer; seeking
                        the nod for colon cancer

DATA: BUSINESS WEEK